Compare SELX & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SELX | ITRM |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | Taiwan | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0M | 24.3M |
| IPO Year | N/A | 2018 |
| Metric | SELX | ITRM |
|---|---|---|
| Price | $0.76 | $0.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 201.2K | ★ 930.9K |
| Earning Date | 05-08-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,974,593.00 | $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $193.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 243.84 | N/A |
| 52 Week Low | $0.52 | $0.26 |
| 52 Week High | $1.85 | $1.75 |
| Indicator | SELX | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 45.27 |
| Support Level | $0.71 | $0.31 |
| Resistance Level | $0.80 | $0.39 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 22.24 | 32.08 |
Semilux International Ltd is a company that operates through its subsidiaries which is an optical and 3D sensing technology company that is involved in the customization, design and supply of optical components and integrated chip for various industries including autonomous driving, intelligent lighting, as well as unmanned aerial vehicles. In collaboration with its clients, TCO conceptualizes and produces high precision optics and sensing modules that are specifically customized to clients' needs for ease of integration in overall design and production. Applications for TCO's products include automotive laser headlight systems, adaptive driving beams (ADB) as well as light detection and autonomous driving systems (LiDAR).
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.